ADK.V - DIAGNOS Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.065
0.000 (0.00%)
At close: 10:48AM EDT
Stock chart is not supported by your current browser
Previous Close0.065
Open0.065
Bid0.060 x 0
Ask0.065 x 0
Day's Range0.065 - 0.065
52 Week Range0.050 - 0.160
Volume85,000
Avg. Volume224,348
Market Cap11.259M
Beta5.14
PE Ratio (TTM)N/A
EPS (TTM)-0.020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire4 days ago

    DIAGNOS to Provide Retinal Image Analysis using its AI Technology to 20/20NOW, the Leading Ocular Telehealth Provider in the United States

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today a three-year agreement to provide its CARA (Computer Assisted Retina Analysis) to 20/20NOW. 20/20NOW will use CARA to upload their retinal images and retrieve the results after analysis by our algorithms to detect anomalies caused by diabetic retinopathy in real time. Identifying diabetic retinopathy (“DR”) in its early stages, when it’s most treatable, is critical to prevent blindness and help at lowering health care costs.

  • GlobeNewswire11 days ago

    DIAGNOS Announces Closing of Private Placement of Common Stocks and Stock Warrants

    BROSSARD, Quebec, Sept. 11, 2018-- DIAGNOS Inc., a leader in early detection of critical health issues through the use of Artificial Intelligence, announces the closing of a private placement, initially ...

  • GlobeNewswire17 days ago

    DIAGNOS Partners with Optina Diagnostics, a Montreal Based Company, to Provide a Web Platform for the Early Detection of Alzheimer Disease

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an agreement to provide a telemedicine platform based on CARA (Computer Assisted Retina Analysis) to Optina Diagnostics (“Optina”) for a period of 3 years. Optina will use DIAGNOS Cloud services to upload images generated by Optina’s hyperspectral camera for early detection of Alzheimer via key biomarkers in the retina of the eye.

  • GlobeNewswire29 days ago

    DIAGNOS Announces Private Placement of Common Stocks and Stock Warrants

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture:ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (“Private Placement”) of up to 1,333,333 units (each a “Unit”) issued at $0.075 per Unit for gross proceeds of up to $100,000. The proceeds will be used to fund marketing and administrative expenses. Shares issued as part of the Private Placement as well as the underlying Shares to be issued upon exercise of the Warrants are subject to a statutory four-month hold period from the date of issuance.

  • GlobeNewswire2 months ago

    DIAGNOS Provides Update on Business Operations

    Diagnos Inc. (“DIAGNOS”, “the Corporation” or “We”) (TSX Venture:ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an update on business operations. This hospital is now screening patients for diabetic retinopathy and hypertension.

  • GlobeNewswire2 months ago

    DIAGNOS Installs its First Retina Screening Clinic based on Artificial Intelligence in Panama

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK), (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the installation of its first retina AI screening clinic, in the Panama’s private health sector. “We are delighted to open our first of 15 Medical clinics in Panama in collaboration with DIAGNOS,” said the CEO and owner of these clinics. “We are looking forward to a long term relationship with our new customer in Panama.

  • GlobeNewswire3 months ago

    DIAGNOS Closes Second and Final Tranche of Private Placement

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture:ADK) (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the closing of a second and final tranche of 11 additional units (each a “Unit”), for gross cash receipts of $550,000, as part of a private placement (“Private Placement”) announced on May 28, 2018 and June 14, 2018. Aggregate cash receipts from the Private Placement amount to $800,000.

  • GlobeNewswire3 months ago

    DIAGNOS Broadens its Collaboration with the Government of Mexico

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (ADK.V), (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an expansion of its screening services with the Mexican government in one northern state of Mexico. As per the agreement, DIAGNOS plans to screen 10,000 patients by December 31, 2018. The Chief Medical Officer of the state also added: “We strongly believe that this preventive approach will strongly benefit our patients and generate substantial savings in future healthcare costs”.

  • GlobeNewswire3 months ago

    DIAGNOS Provides Financing Updates

    BROSSARD, Quebec, June 29, 2018-- DIAGNOS Inc., a leader in early detection of critical health issues through the use of its FL AI RE platform based on Artificial Intelligence, provides updates on financing ...

  • With A -11.24% Earnings Drop Lately, Did Diagnos Inc (CVE:ADK) Underperform Its Industry?
    Simply Wall St.7 months ago

    With A -11.24% Earnings Drop Lately, Did Diagnos Inc (CVE:ADK) Underperform Its Industry?

    When Diagnos Inc (TSXV:ADK) released its most recent earnings update (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...

  • Marketwired9 months ago

    DIAGNOS Successfully Passed ISO Annual Surveillance Audit

    DIAGNOS Inc. , a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence , announces today that it has successfully passed the ISO 13485 ...